NCT04549662View on ClinicalTrials.gov

The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

February 12, 2024

Study Completion Date

February 12, 2024

Conditions
Hepatopancreaticobiliary (HPB) MalignancySurgery
Interventions
DIETARY_SUPPLEMENT

Active A

Powdered formula containing whey protein and arginine

DIETARY_SUPPLEMENT

Active B

Powdered formula containing whey protein

DIETARY_SUPPLEMENT

Lipid bolus

Omega-3 fatty acids

DIETARY_SUPPLEMENT

Placebo oil

Control placebo oil that does not contain omega-3 fatty acids

Trial Locations (2)

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
collaborator

Enhanced Medical Nutrition

INDUSTRY

collaborator

Sunnybrook Health Sciences Centre Clinical Research Grant Competition

UNKNOWN

collaborator

Sunnybrook Health Sciences Centre AFP Innovation Fund

UNKNOWN

lead

Sunnybrook Health Sciences Centre

OTHER